Abbott has agreed to pay $385 million to resolve investigations and lawsuits related to its 2022 recall of powdered infant formula from its Sturgis, Michigan facility. The settlement does not imply any fault or liability, and the US government has closed its criminal investigation. Tests showed no unopened Abbott formula tested positive for Cronobacter sakazakii, a bacterium linked to infant illnesses. The CDC found no definitive link between the Sturgis plant and the reported cases, emphasizing contamination often occurs in homes. Abbott remains committed to product safety and serving families.
Abbott Laboratories (ABT) trades at USD 103.21 on Pluang as of Sep 14, 2026 23:01 WIB, showing a 1.23% gain for the day. The company’s market capitalization stands at $176.41 billion, reflecting its significant presence in the health sector. This trading performance comes following Abbott’s agreement to pay $385 million to resolve claims related to its 2022 infant formula recall, as detailed in the news.
Abbott has introduced Ensure Max Protein 3-in-1 Muscle Support, a powder combining 30g of protein, 5g of creatine monohydrate, and 3g of calcium HMB to help build, recover, and preserve muscle. This product targets growing consumer interest in muscle...
In 2026, both Medtronic and Abbott stocks have declined, altering their dividend yields and valuations. Medtronic now offers a higher dividend yield of 3.3% versus Abbott's 2.56%, making it more attractive for retirees needing income. Abbott, however...
Abbott received FDA approval for updates to its CardioMEMS HF System, enabling U.S. heart failure patients to view pulmonary artery pressure (PAP) readings on the new CardioGuide HF App. This app helps patients monitor their condition and receive per...
